Two US biotech CEOs charged with defrauding investors about HIV antibody approval status
MLex Summary: Nader Pourhassan, the former chief executive of publicly traded biotechnology company CytoDyn, and Kazem Kazempour, the CEO of Amarex Clinical Research, were charged by the US with conspiring to criminally...To view the full article, register now.
Already a subscriber? Click here to view full article